StreetInsider.com News Articles

Eledon reports insulin independence in all 12 type 1 diabetes patients

Mon, 08 Jun 2026 07:02:36 -0400

Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN) reported that all 12 patients in an investigator-initiated trial achieved insulin independence following islet transplantation using its experimental drug tegoprubart.

The study, conducted at University of Chicago Medicine, showed patients no longer required external insulin therapy to manage their type 1 diabetes after receiving the treatment. All participants also achieved hemoglobin A1C levels below 6.5%, with an average of approximately 5.4%, representing an improvement of about 2.6% from baseline levels.

No severe hypoglycemic episodes occurred post-transplant, compared to all patients experiencing recurrent severe episodes before treatment. The study followed patients for a median of 8 months and

Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine

Mon, 08 Jun 2026 07:00:00 -0400

– All 12 patients in study (100%) achieved insulin independence, producing their own insulin and no longer requiring exogenous insulin therapy to manage their T1D

– All 12 patients also achieved an HbA1c below 6.5%, with a mean most recent HbA1c of approximately 5.4%, representing an approximately 2.6% average improvement in HbA1c from baseline

– No severe hypoglycemic episodes were reported post-transplant, compared with a history of recurrent severe hypoglycemic events prior to transplantation in all enrolled patients

IRVINE, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN)

Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine

Mon, 08 Jun 2026 07:00:00 -0400

– All 12 patients in study (100%) achieved insulin independence, producing their own insulin and no longer requiring exogenous insulin therapy to manage their T1D

– All 12 patients also achieved an HbA1c below 6.5%, with a mean most recent HbA1c of approximately 5.4%, representing an approximately 2.6% average improvement in HbA1c from baseline

– No severe hypoglycemic episodes were reported post-transplant, compared with a history of recurrent severe hypoglycemic events prior to transplantation in all enrolled patients

IRVINE, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN)

Eledon to present islet transplant trial data at diabetes conference

Thu, 04 Jun 2026 16:31:58 -0400

Eledon Pharmaceuticals (NASDAQ: ELDN) announced that updated results from an investigator-initiated trial of its drug tegoprubart will be presented at the American Diabetes Association's 86th Scientific Sessions on June 7, 2026, in New Orleans.

The presentation will be delivered by Piotr Witkowski, M.D., Ph.D., Director of the Pancreas and Islet Transplant Program at UChicago Medicine, who is conducting the trial at the University of Chicago Medicine Transplant Institute. The study examines tegoprubart's use in islet transplantation for patients with Type 1 diabetes.

The oral presentation, titled "Anti-CD40L to Induce Graft Survival and Function in Islet Allotransplantation," is scheduled for 2:30 p.m. to

Eledon to present islet transplant trial data at diabetes conference

Thu, 04 Jun 2026 16:31:58 -0400

The oral presentation, titled "Anti-CD40L to Induce Graft Survival and Function in Islet Allotransplantation," is scheduled for 2:30 p.m. to

Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific

Thu, 04 Jun 2026 16:31:00 -0400

IRVINE, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that updated results from an investigator-initiated trial being conducted at the University of Chicago Medicine Transplant Institute will be presented by Piotr Witkowski, M.D., Ph.D., Director of the Pancreas and Islet Transplant Program at UChicago Medicine, at the American Diabetes Association 86th Scientific Sessions, taking place June 5-9, 2026, in New Orleans, Louisiana.

Details of the oral presentation are as follows: